These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 18973168)

  • 1. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
    Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
    ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
    Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).
    Sessions EH; Chowdhury S; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7113-8. PubMed ID: 22018789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.
    Matter H; Scheiper B; Steinhagen H; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5487-92. PubMed ID: 21840215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
    Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
    Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
    Soth M; Abbot S; Abubakari A; Arora N; Arzeno H; Billedeau R; Dewdney N; Durkin K; Frauchiger S; Ghate M; Goldstein DM; Hill RJ; Kuglstatter A; Li F; Loe B; McCaleb K; McIntosh J; Papp E; Park J; Stahl M; Sung ML; Suttman R; Swinney DC; Weller P; Wong B; Zecic H; Gabriel T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3452-6. PubMed ID: 21515047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
    Liddle J; Bamborough P; Barker MD; Campos S; Cousins RP; Cutler GJ; Hobbs H; Holmes DS; Ioannou C; Mellor GW; Morse MA; Payne JJ; Pritchard JM; Smith KJ; Tape DT; Whitworth C; Williamson RA
    Bioorg Med Chem Lett; 2009 May; 19(9):2504-8. PubMed ID: 19349179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
    Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
    Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
    Fang X; Yin Y; Chen YT; Yao L; Wang B; Cameron MD; Lin L; Khan S; Ruiz C; Schröter T; Grant W; Weiser A; Pocas J; Pachori A; Schürer S; Lograsso P; Feng Y
    J Med Chem; 2010 Aug; 53(15):5727-37. PubMed ID: 20684608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.
    Kast R; Schirok H; Figueroa-Pérez S; Mittendorf J; Gnoth MJ; Apeler H; Lenz J; Franz JK; Knorr A; Hütter J; Lobell M; Zimmermann K; Münter K; Augstein KH; Ehmke H; Stasch JP
    Br J Pharmacol; 2007 Dec; 152(7):1070-80. PubMed ID: 17934515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
    Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
    Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
    J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
    Waelchli R; Bollbuck B; Bruns C; Buhl T; Eder J; Feifel R; Hersperger R; Janser P; Revesz L; Zerwes HG; Schlapbach A
    Bioorg Med Chem Lett; 2006 Jan; 16(1):108-12. PubMed ID: 16236504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
    Sessions EH; Yin Y; Bannister TD; Weiser A; Griffin E; Pocas J; Cameron MD; Ruiz C; Lin L; Schürer SC; Schröter T; LoGrasso P; Feng Y
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6390-3. PubMed ID: 18996009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imidazo[2,1 -b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition.
    Andreani A; Cavalli A; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Recanatini M; Garnier M; Meijer L
    Anticancer Drug Des; 2000 Dec; 15(6):447-52. PubMed ID: 11716438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chroman-3-amides as potent Rho kinase inhibitors.
    Chen YT; Bannister TD; Weiser A; Griffin E; Lin L; Ruiz C; Cameron MD; Schürer S; Duckett D; Schröter T; LoGrasso P; Feng Y
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6406-9. PubMed ID: 18990570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of rho kinase inhibitors (III).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Sato M; Sugiyama T; Fukushima K; Taya S; Amano M; Kaibuchi K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(2):1022-33. PubMed ID: 17084087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.